Astellas Pharma and Pfizer have announced unprecedented results from the pivotal Phase 3 EV-303 clinical trial (KEYNOTE-905), with the combination of PADCEV (enfortumab vedotin) and MSD's KEYTRUDA (pembrolizumab) delivering significant survival benefits for cisplatin-ineligible patients with muscle-invasive bladder cancer. …
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Orthocell boosts balance sheet with capital raise to drive nerve repair product growth
October 19, 2025 - - Australian Biotech -
Amplia targets US market expansion as FAK inhibitor shows promise in pancreatic cancer
October 19, 2025 - - Australian Biotech -
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 - - Latest News -
AdvanCell unveils promising first clinical results for 212Pb-ADVC001 in prostate cancer
October 19, 2025 - - Australian Biotech -
Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access
October 18, 2025 - - Latest News -
Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer
October 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 October
October 17, 2025 - - Podcast